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Abstract
Background: The protein C pathway plays an important role in the maintenance of endothelial barrier function and in the
inflammatory and coagulant processes that are characteristic of patients on dialysis. We investigated whether common
single nucleotide variants (SNV) in genes encoding protein C pathway components were associated with all-cause 5 years
mortality risk in dialysis patients.
Methods: Single nucleotides variants in the factor V gene (F5 rs6025; factor V Leiden), the thrombomodulin gene (THBD
rs1042580), the protein C gene (PROC rs1799808 and 1799809) and the endothelial protein C receptor gene (PROCR
rs867186, rs2069951, and rs2069952) were genotyped in 1070 dialysis patients from the NEtherlands COoperative Study on
the Adequacy of Dialysis (NECOSAD) cohort) and in 1243 dialysis patients from the German 4D cohort.
Results: Factor V Leiden was associated with a 1.5-fold (95% CI 1.1–1.9) increased 5-year all-cause mortality risk and carriers
of the AG/GG genotypes of the PROC rs1799809 had a 1.2-fold (95% CI 1.0–1.4) increased 5-year all-cause mortality risk. The
other SNVs in THBD, PROC, and PROCR were not associated with 5-years mortality.
Conclusion: Our study suggests that factor V Leiden and PROC rs1799809 contributes to an increased mortality risk in
dialysis patients.
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Introduction
The protein C pathway plays an important role in endothelial
barrier function and in inflammatory and anticoagulant processes
[1]. Protein C activation occurs on the endothelial cell membrane
by thrombin bound to thrombomodulin and this is enhanced
when protein C is bound to the endothelial protein C receptor.
Activated protein C together with its cofactor protein S inactivates
the procoagulant factors Va and VIIIa. Activated protein C
resistance is often caused by a variant of factor V (factor V Leiden),
that abrogates one of the inactivation sites in factor Va [2]. Besides
anticoagulant properties, activated protein C has direct cytopro-
tective effects on endothelial cells that include anti-inflammatory
actions, anti-apoptotic activities, and stabilization of endothelial
barriers. These effects are largely mediated by activation of
protease activated receptors [3–7].
The crucial role of the protein C pathway in endothelial
function, coagulation, and inflammation became evident in several
studies [8–12]. The importance of the protein C system is most
clearly demonstrated by the massive thrombotic complications
occurring in infants with severe protein C deficiency due to genetic
abnormalities [8] and the increased risk of venous thrombosis in
adults with a genetic defect resulting in decreased protein C levels
[9]. In severe sepsis patients with a high mortality risk treatment
with activated protein C reduced mortality, probably through its
anti-inflammatory and anticoagulant activities [10]. In addition,
low plasma protein C levels have been shown to increase the risk
of ischemic stroke [11]. Finally, particular combinations of variants
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in the thrombomodulin, protein C, and factor V genes seem to
increase the risk of cardiovascular events in the general population
[12].
Patients on dialysis have a high mortality risk due to endothelial
damage and subsequent cardiovascular diseases [13]. Dialysis
patients also have a high risk of dying from dialysis treatment
failure [13], which is associated with thrombotic events (i.e.
vascular access thrombosis and catheter thrombosis) and infections
[13]. Genetic variation in the protein C pathway could influence
the mortality risk by changing processes related to endothelial
damage, by influencing inflammatory response, and by increasing
or decreasing the chance of thrombotic events associated with
treatment failure. We hypothesized that single nucleotide variants
encoding protein C pathway components or targets might
influence mortality rates in dialysis patients.
We selected seven single nucleotide variants (SNVs) that are
known to influence levels or activity of proteins in the protein C
pathway or have been associated with venous thrombosis, arterial
thrombosis or mortality in the general population: factor V (F5)
rs6025 (factor V Leiden) [2], thrombomodulin (THBD) rs1042580
[12,14], protein C (PROC) rs1799809 and rs1799808 [15], and
protein C receptor (PROCR) rs867186, rs2069952, and
rs2069952.16 We investigated the association between these SNVs
and all-cause and cause-specific (cardiovascular and non-cardio-
vascular) mortality in the NEtherlands COoperative Study on the
Adequacy of Dialysis (NECOSAD) cohort and the German
Diabetes Dialysis Study (4D-study).
Methods and Materials
Patients
The Netherlands Cooperative Study on the Adequacy of
Dialysis (NECOSAD) is a prospective multicenter cohort study
in which incident adult dialysis patients from 38 dialysis centers in
the Netherlands were included. The Medical Review Ethics
Committee of the Leiden University Medical Center approved the
study. All patients gave written informed consent. Eligibility
criteria included age older than 18 years, and no previous renal
replacement therapy (transplantation or dialysis). For the current
analyses, we used data from patients who were included between
June 1997 and June 2007 in 23 dialysis centers that approved
DNA analysis. Information was gathered from patients until date
of death or date of censoring, i.e. transfer to a nonparticipating
dialysis center, withdrawal from the study, transplantation, or end
of the follow-up period in June 2009, whichever occurred first.
Demographic and clinical data
Data on age, sex, primary kidney disease, and cardiovascular
disease were collected at the start of dialysis treatment. Pre-existing
cardiovascular disease was defined as a history of angina pectoris,
myocardial infarction, heart failure, ischemic stroke, or claudica-
tion at the time of inclusion.
Single nucleotide variants
Blood samples were collected for DNA analysis. We genotyped
one SNV in the factor V gene (F5 rs6025; factor V Leiden), one
SNV in the thrombomodulin gene (THBD rs1042580), two SNVs
in the protein C gene (PROC rs1799809 and rs1799808), and three
SNVs in the protein C receptor gene (PROCR rs867186,
rs2069951, and rs2069952) using TaqMan SNV Genotyping
Assays (Applied Biosystems, Foster City, CA, USA) as described
previously [14–17].
Mortality
We classified causes of death according to the codes of the
European Renal Association-European Dialysis and Transplanta-
tion Association (ERA-EDTA) which is a standardized classifica-
tion of death causes in dialysis patients [18]. We grouped death
causes into cardiovascular and non-cardiovascular mortality.
Cardiovascular mortality was defined as death due to myocardial
ischemia and infarction (code 11); cardiac arrest/sudden death
(code 15); cardiac failure/fluid overload/pulmonary edema (codes
14,16,18); hyperkalemia/hypokalemia (code 12,17); pulmonary
embolism (code 21); cerebrum-vascular accident (code 22);
hemorrhage from ruptured vascular aneurysm (code 26); mesen-
teric infarction (code 29); cause of death uncertain/unknown (code
0). All other deaths were designated as non-cardiovascular
mortality.
Replication
For independent replication of the results of the NECOSAD
study, we analyzed data from the German Diabetes Dialysis Study
(4D-study). Methods of the 4D-study have been described in detail
previously [19]. Briefly, the 4D-study was a double-blind,
randomized trial on the effect of atorvastatin in hemodialysis
patients with type 2 diabetes mellitus who had less than two years
of previous hemodialysis treatment. The primary endpoint of was
a composite of cardiac death, non-fatal myocardial infarction and
stroke, whichever occurred first. Patients were randomly assigned
to either 20 mg of atorvastatin or placebo once daily until the date
of death, censoring, or the end of study in March 2004.
Atorvastatin showed no effect on the composite primary end
point [19]. The genotyping of the SNV in the factor V gene (F5
rs6025; factor V Leiden), the SNV in the thrombomodulin gene
(THBD rs1042580), the two SNVs in the protein C gene (PROC
rs1799809 and rs1799808), and the three SNVs in the protein C
receptor gene (PROCR rs867186, rs2069951, and rs2069952) were
the same as described above for the NECOSAD cohort. The SNV
in the factor V gene (F5 rs6025; factor V Leiden), the SNV in the
thrombomodulin gene (THBD rs1042580), and the SNV in the
protein C receptor gene (PROCR rs867186) were genotyped earlier
than the other SNVs, therefore the numbers vary for these SNVs
as compared with the other SNVs. Mortality was also categorized
into cardiovascular and non-cardiovascular deaths.
Statistical analysis
The baseline characteristics are presented as median and 5th–
95th percentiles for continuous variables, and as percentages for
categorical variables. Distributions of genotypes were compared by
the chi-square test to test for Hardy-Weinberg equilibrium. We
calculated pooled hazard ratios (HRs) with 95% confidence
intervals (95% CIs) for all-cause, cardiovascular, and non-
cardiovascular mortality by Cox’s regression analysis to study
the effect of the seven SNVs on 5-year mortality from start of
dialysis in the NECOSAD and 4D-study together. Moreover, we
investigated the effect on mortality of combinations of THBD
rs1042580 and single nucleotide variants that increased the
mortality risk of dialysis patients in our study, since a previous
study found associations between the combination of single
nucleotide variants in the protein C pathway and THBD
rs1042580 in the risk of cardiovascular diseases [12]. Furthermore,
we calculated HRs with 95% CIs separately for the NECOSAD
cohort and 4D-study. In addition, we repeated the analyses in the
NECOSAD cohort for only hemodialysis patients with diabetes
mellitus, since the 4D-study consists of only hemodialysis patients
with diabetes mellitus. HRs were calculated for homozygous or
heterozygous carriers of the rare alleles (except for rs2069952 for
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which the risk allele was the common major allele) of the SNVs
compared to non-carriers. We reported unadjusted HRs, since
adjustment in genetic association studies could potentially
introduce interference in the causal pathway and thereby bias
through overadjustment [20]. We used SPSS statistical software
(version 17.0; SPSS, Chicago) for all statistical analyses.
Results
A total of 1070 patients from the NECOSAD cohort and 1243
patients from the 4D cohort were genotyped for the seven SNVs.
Baseline characteristics of the 1070 patients from the NECOSAD
cohort and 1243 patients from the 4D cohort are shown in Table 1.
In contrast to the NECOSAD cohort, the 4D cohort consisted
only of hemodialysis patients with diabetes mellitus. In the
NECOSAD cohort, 140 hemodialysis patients (20.7%) had
diabetes mellitus.
Table 2 shows the genotype and allele frequencies for the seven
SNVs. All SNVs in the NECOSAD cohort were in Hardy-
Weinberg equilibrium, except PROC rs1799809 (p-value 0.002). In
the 4D cohort, F5 rs6025 (factor V Leiden) (p-value,0.001),
PROC rs1799808 (p-value ,0.036), and PROCR rs2069952 (p-
value 0.001) were not in Hardy-Weinberg equilibrium (Table 2).
Of the 1070 patients from the NECOSAD cohort, 401 died
within 5 years of follow-up; 185 patients due to cardiovascular
causes and 216 due to non-cardiovascular causes. In the 4D
cohort, 594 patients died within 5 years of follow-up (297 patients
due to cardiovascular causes and 297 due to non-cardiovascular
causes).
Factor V (Leiden) rs6025
Factor V Leiden was associated with a 1.5-fold (95% CI 1.1–
1.9) increased year all-cause mortality risk in the pooled results.
The hazard ratios were 1.4 (95% CI 0.9–2.1) in the total
NECOSAD cohort and 1.6 (95% CI 1.1–2.2) in the 4D-study
(Table 3). Restricting the analyses to diabetic patients with
hemodialysis in the NECOSAD study (similar to the 4D study
which only includes diabetic hemodialysis patients), factor V
Leiden was associated with a 2.1-fold (95% CI 1.0–4.5) increased
5-year all-cause mortality risk (Table 3).
As compared with THBD rs1042580 AA genotype in the
absence of factor V Leiden, the combination of factor V Leiden
and THBD rs1042580 AA genotype resulted in a 1.5-fold (95% CI
0.9–2.4) increased mortality risk, the combination of THBD
rs1042580 AA genotype in the absence of factor V Leiden resulted
in a 1.0-fold (95% CI 0.9–1.1) increased mortality risk, and the
combination of factor V Leiden and THBD rs1042580 AG/GG
genotypes resulted in a 1.4-fold (95% CI 1.0–2.0) mortality risk.
Thrombomodulin, protein C and protein C receptor
variants
As compared to the AA genotype in PROC rs1799809, carriers
of the AG/GG genotypes had a 1.2-fold (95% CI 1.0–1.4)
increased 5-year all-cause mortality risk (Table 3). As compared
with PROC rs1799809 AA genotype and THBD rs1042580 AA
genotype, the combination of PROC rs1799809 AG/GG geno-
types and THBD rs1042580 AA genotype resulted in a 1.1-fold
(95% CI 0.9–1.4) increased mortally risk, the combination of
PROC rs1799809 AA genotype and THBD rs1042580 AG/GG
genotypes resulted in a 0.9-fold (95% CI 0.7–1.2) increased
mortally risk, and the combination of PROC rs1799809 AG/GG
genotype and THBD rs1042580 AG/GG genotype resulted in a
1.2-fold (95% CI 0.9–1.5) increased mortally risk.
PROC rs1799809, THBD rs1042580, PROC rs1799808, PROCR
rs867186, PROCR rs2069951, and PROCR rs2069952 were not
associated with all-cause mortality in the NECOSAD and the 4D
cohorts (Table 3).
Discussion
This candidate-gene study assessed the 5-years mortality risk
while on dialysis treatment for seven genetic variants that influence
levels or activity of proteins in the protein C pathway: one SNV in
the factor V gene (factor V Leiden), two SNVs in the protein C
gene (PROC), one SNV in the thrombomodulin gene (THBD) and
three SNVs (tagging three haplotypes) in the protein C receptor
gene (PROCR). We found that factor V Leiden was associated with
a 1.5-fold (95% CI 1.1–1.9) increased 5-year all-cause mortality
risk and that PROC rs1799809 was associated with a 1.2-fold (95%
CI 1.0–1.4) increased 5-year all-cause mortality risk. Furthermore,
we showed that THBD rs1042580, PROC rs1799808, PROCR
rs867186, PROCR rs2069951, and PROCR rs2069952 were not
associated with an increased mortality risk.
Studies in the general population have shown an association
between factor V Leiden and an increased risk of different adverse
outcomes, including venous thrombosis [17], ischemic stroke [21],
and myocardial infarction [22]. We showed in the current study
that factor V Leiden was associated with increased all-cause
mortality in dialysis patients. Other studies did not find an
increased all-cause mortality risk for factor V Leiden in the general
population and in thrombophilic families [23,24]. However, it
could be the interaction between dialysis and factor V Leiden that
Table 1. Baseline characteristics.
NECOSAD N=1070 4D-study N=1243
Age (years), median (5th-95th percentile) 62.2 (33.0–80.2) 66.0 (51.0–78.0)
Males, % 62.9 54.1
Body mass index (kg/m2), median (5th–95th percentile) 24.3 (19.2–33.2) 26.7 (20.7–36.3)
Dialysis duration (months), median (5th–95th percentile) 0 6.0 (1.1–22.5)
Dialysis modality,%
Hemodialysis 63.4 100
Peritoneal dialysis 36.6 0
History of diabetes mellitus, % 20.7 100
Cardiovascular disease,% 35.2 29.5
doi:10.1371/journal.pone.0097251.t001
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could lead to an increased mortality, which is not present in the
general population. Previous studies on factor V in the dialysis
population have been focused on arteriovenous access failure. A
recent study showed that a factor V gene SNV (rs6019) was
associated with arteriovenous graft failure in dialysis patients
suggesting an association between factor V SNVs and adverse
outcomes in dialysis patients [25], which is in line with our study.
Factor V Leiden represents a single nucleotide variant in the
Factor V gene, encoding a change in the protein from an arginine
at position 506 to a glutamine. Since this amino acid is normally
the cleavage site for activated protein C, the mutation prevents
efficient inactivation of factor V. When factor V remains active, it
facilitates overproduction of thrombin leading to a procoagulant
state. Several mechanisms might provide plausible explanations
for the higher mortality risk in dialysis patients associated with
factor V Leiden. First, factor V Leiden in combination with pre-
existing and highly prevalent endothelial damage could lead to
excess mortality from cardiovascular events. Second, factor V
Leiden has been associated with venous thrombosis [14,16,17,26].
The excess mortality could have been caused by fatal pulmonary
embolisms due to the procoagulant changes due to factor V
Leiden in combination with the start of dialysis which is also
associated with an increased risk of venous thrombosis [27,28].
Arguing against this explanation is that in our study confirmed
pulmonary embolism was the cause of death in only three patients,
but pulmonary embolisms as cause of death might have gone
undetected or misclassified as for example sudden cardiac death.
Third, one of the main complications in dialysis therapy is clot
formation and thrombosis in vascular accesses [29]. Factor V
Leiden is associated with procoagulant changes and could
therefore lead to treatment failure in dialysis patients. Previous
studies have reported an increased risk of arteriovenous access
failure in patients with factor V SNVs [30,31].
THBD rs1042580 AG/GG genotypes have been associated with
venous thrombosis in the general population [14]. In addition, the
combination of THBD rs1042580 with different Factor V SNVs
was associated with an increased risk of cardiovascular events [12].
Other THBD SNVs have also been associated with cardiovascular
outcomes when combined with PROC SNVs or factor V Leiden in
the general population [12]. However, we did not find an
association between THBD rs1042580 AG/GG genotypes and
mortality in dialysis patients. Furthermore, we did not find an
important interaction between THBD rs1042580 and factor V
Leiden and between THBD rs1042580 and PROC rs1799809.
In contrast to previous studies in sepsis patients, we found no
association between the PROC rs1799808 and mortality. However,
we found that PROC rs1799809 was associated with a small
increased (hazard ratio 1.2, 95% CI 1.0–1.4) mortality risk.
Haplotypes tagged by these SNVs have been associated with
decreased survival and increased organ dysfunction in severe sepsis
patients [32,33]. An earlier study found that PROC rs1799808 was
less important in the determination of protein C levels, indicating
that the effect on protein C levels was mainly mediated by the
PROC rs1799809 [15]. Studies in the general population on
PROCR rs867186, PROCR rs2069951, and PROCR rs2069952
have been inconsistent in the risk of venous thrombosis [15,16,26]
and arterial thrombosis [34,35]. We did not find an association
between these SNVs and mortality.
The genotype distribution of PROC rs1799809 deviated from
Hardy-Weinberg equilibrium in the NECOSAD study and the
genotype distribution of F5 rs6025 (factor V Leiden), PROC
rs1799808, and PROCR rs2069952 were not in Hardy-Weinberg
equilibrium in the 4D cohort. It is likely that in diseased
populations, such as dialysis patients, selection could have resulted
in deviations from Hardy-Weinberg equilibrium.
A potential limitation of our study is that we replicated our
results in a dialysis population consisting of hemodialysis patients
with diabetes mellitus. For most of the SNVs this was not a
problem, since there were no large differences when we restricted
the NECOSAD cohort to hemodialysis patients with diabetes
mellitus. However, in the 4D-study, we could not investigate the
association between mortality and the protein C SNVs in
peritoneal dialysis patients and in patients without diabetes
mellitus. Furthermore, although we included more than 2000
dialysis patients, our study could be underpowered to detect small
differences. In addition, we did not correct for multiple testing,
since in this candidate gene study the single nucleotide were
chosen based on a priori hypotheses.
In conclusion, our study suggests that factor V Leiden and
PROC rs1799809 contributes to an increased mortality risk in
dialysis patients. This study is the first to investigate the association
between protein C pathway SNVs and mortality in large cohorts
of dialysis patients.
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